CoChat
Sign Up
Cited by 25Erythropoietin and Anemia TreatmentCancer, Hypoxia, and MetabolismAngiogenesis and VEGF in Cancer

Recombinant Human Erythropoietin Alpha Improves the Efficacy of Radiotherapy of a Human Tumor Xenograft, Affecting Tumor Cells and Microvessels

Lövey, József, Bereczky, Bíborka, Gilly, Réka, Kenessey, István, Rásó, Erzsébet, Simon, Erika, Dobos, Judit, Vágó, Ágnes +4 more·2008·Strahlentherapie und Onkologie
DOI 10.1007/s00066-008-1745-2
Open this paper in CoChat — free account

Abstract

Background and purpose Tumor-induced anemia often occurs in cancer patients, and is corrected by recombinant human erythropoietins (rHuEPOs). Recent studies indicated that, besides erythroid progenitor cells, tumor and endothelial cells express erythropoietin receptor (EPOR) as well; therefore, rHuEPO may affect their functions. Here, the effect of rHuEPOalpha on irradiation in EPOR-positive human squamous cell carcinoma xenograft was tested.Material and methods A431 tumor-bearing SCID mice were treated from the tumor implantation with rHuEPOalpha at human-equivalent dose. Xenografts were irradiated (5 Gy) on day 14, and the final tumor mass was measured on day 22. The systemic effects of rHuEPOalpha on the hemoglobin level, on tumor-associated blood vessels and on hypoxia-inducible factor-(HIF-)1alpha expression of the tumor xenografts were monitored. The proliferation, apoptosis and clonogenic capacity of A431 cancer cells treated with rHuEPOalpha and irradiation were also tested in vitro.Results In vitro, rHuEPOalpha treatment alone did not modify the proliferation of EPOR-positive A431 tumor cells but enhanced the effect of irradiation on proliferation, apoptosis and clonogenic capacity. In vivo, rHuEPOalpha administration compensated the tumor-induced anemia in SCID mice and decreased tumoral HIF-1alpha expression but had no effect on tumor growth. At the same time rHuEPOalpha treatment significantly increased the efficacy of radiotherapy in vivo (tumor weight of 23.9 +/- 4.7 mg and 34.9 +/- 4.6 mg, respectively), mediated by increased tumoral blood vessel destruction.Conclusion rHuEPOalpha treatment may modulate the efficacy of cancer radiotherapy not only by reducing systemic hypoxia and tumoral HIF-1alpha expression, but also by destroying tumoral vessels.

Integrity signals

Registry

Crossref · 10.1007/s00066-008-1745-2

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Erythropoiesis stimulating agent (ESA) treatment may promote the efficacy of radiotherapy, as observed in preclinical models.

    “promoting efficacy of radiotherapy [81], asx observed in preclinical models.”

    From Hypoxia Signaling in Cancer: From Basics to Clinical Practice (2021) · cites this paper as [81]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Lövey, J., Bereczky, B., Gilly, R., Kenessey, I., Rásó, E., Simon, E., Dobos, J., Vágó, Á., Kásler, M., Döme, B., Tímár, J., & Tóvári, J.
Affiliations
  • National Institute of Oncology (HU)
  • Országos Korányi Tbc és Pulmonológiai Intézet (HU)
  • Semmelweis University (HU)
Corresponding author
Tóvári, József
ORCID
Venue
Strahlentherapie und Onkologie
Publisher
Springer Science and Business Media LLC
Published
2008-01
Volume
184
Issue
1
Pages
1-7
ISSN
  • 0179-7158 (ISSN-L)
  • 1439-099X
DOI
10.1007/s00066-008-1745-2
OpenAlex
W1496148327
Cited by
25
References
40
Citations by year
2024: 1 · 2023: 1 · 2021: 2 · 2016: 2 · 2015: 1 · 2014: 1 · 2013: 1 · 2012: 1
FWCI
3.23
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Strahlentherapie und Onkologie (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
Keywords
radiotherapy efficacy, erythropoietin receptor, squamous cell carcinoma, A431 cells, tumor xenografts, hypoxia-inducible factor-1α, tumor vasculature, apoptosis, clonogenicity, tumor hypoxia
MeSH terms
Animals, Carcinoma, Squamous Cell, Cell Division, Erythropoietin, Female, Humans, Neoplasm Transplantation, Radiation-Sensitizing Agents, Recombinant Proteins, Soft Tissue Neoplasms, Transplantation, Heterologous, Tumor Stem Cell Assay, Mice, SCID, Apoptosis, Cell Line, Tumor, Mice, In Vitro Techniques

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review